Cambridge Cognition wins new £750,000 digital health contract

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a new contract providing cognitive tests and electronic clinical outcome assessments for an Alzheimer’s trial. The total Contract is worth approximately £750,000 over two years, with a considerable proportion of the revenue for the Company expected to be received in 2021.

Alzheimer’s trials have seen significant disappointments in recent years, so this pharmaceutical client is taking a new approach with a cutting-edge part-virtual clinical trial which combines in-person and remote testing. Cambridge Cognition is in a unique position to support the delivery of this trial with expertise in both gold-standard cognitive assessment and innovative digital health solutions for frequent, remote testing.

To establish the cognitive impact of the drug, patients will complete CANTABTM cognitive assessments both in clinic and at home. The Company will also capture the important caregiver perspective by deploying an engaging mobile application. To deliver the Contract, Cambridge Cognition will configure existing modules developed for previous clinical trials rather than undertaking bespoke software development.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“We are delighted to be supporting the continuing pursuit of a new Alzheimer’s therapeutic with all three of our major commercial solutions: CANTAB™ cognitive assessments, eCOA questionnaires, and digital health applications. The disease burden for caregivers and family members cannot be overlooked and so we are particularly excited to play such an active role in capturing their experience for the trial.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions